A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Status:
RECRUITING
Trial end date:
2028-08-08
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).